Aurinia Pharmaceuticals Inc
AUPH
Jodie situation report
Aurinia Pharmaceuticals Inc's move is being confirmed by its market group.
No new filing conclusion is available. 14 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- At least 12 of 18 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ROIV begins moving with the group.
Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.
Who this business touches
The relationships behind AUPH
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PKGPackaging Corporation of AmericasupplierFeb 26, 2026 ▾
“Packaging We use a sole supplier for the blistering and packaging of LUPKYNIS commercial cartons for sale in the U.S.”
TEVATeva Pharmaceutical Industries LimitedpartnerFeb 26, 2026 ▾
“Ltd., Galenicum Health S.L.U., Zydus Pharmaceuticals (USA) Inc., Teva Pharmaceuticals, Inc., Dr.”
Depended on by
VERAVera Therapeutics, Inc.competitorMay 7, 2026 ▾
“We consider the most advanced direct competitor to VT-109 to be the BCMA Fc-fusion protein from Aurinia Pharmaceuticals Inc., which is currently in Phase 1 clinical development.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AUPH is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.